SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:su-190647"
 

Sökning: onr:"swepub:oai:DiVA.org:su-190647" > Use of Cardiovascul...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005334naa a2200589 4500
001oai:DiVA.org:su-190647
003SwePub
008210303s2020 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:145543924
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-1906472 URI
0247 a https://doi.org/10.3389/fphar.2020.6081362 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1455439242 URI
040 a (SwePub)sud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Cong, Lin4 aut
2451 0a Use of Cardiovascular Drugs for Primary and Secondary Prevention of Cardiovascular Disease Among Rural-Dwelling Older Chinese Adults
264 c 2020-12-18
264 1b Frontiers Media SA,c 2020
338 a print2 rdacarrier
520 a Cardiovascular risk factors and related disorders are common among older adults, and use of various classes of cardiovascular (CV) drugs could reduce the risk of cardiovascular disease (CVD). However, data are sparse with regard to the use of CV drugs among rural-dwelling older adults in China. Therefore, this population-based study aimed to describe use of CV drugs among older adults living in the rural communities in China, while taking into account the use of CV drugs for primary and secondary prevention of CVDs. This study included 5,246 participants (age >= 65 years; 57.17% women; 40.68% illiteracy) in the baseline examination of the MIND-China study. In March-September 2018, data on health-related factors, CVDs (ischemic heart disease, atrial fibrillation, heart failure, and stroke), and CV drug use were collected via face-to-face survey, clinical examination, and laboratory tests. We classified CV drugs according to the Anatomical Therapeutic Chemical classification system for western medications and specific cardiovascular effects for the products of traditional Chinese medicine (TCM). We conducted descriptive analysis. The overall prevalence of major cardiovascular risk factors ranged from 14.30% in diabetes and 23.81% in dyslipidemia to 66.70% in hypertension, and CVDs affected 35.07% of all participants (36.28% in women vs. 33.47% in men, p = 0.035). In the total sample, calcium channel blockers (C08) were most commonly used (10.39%), followed by TCM products (7.64%), hypoglycemic agents (A10, 4.73%), renin-angiotensin system (RAS)-acting agents (C09, 4.61%), and lipid-lowering agents (C10, 4.17%). The proportions of CV drugs for primary prevention (i.e., use of CV drugs among people without CVD) were 3.14% for antithrombotic agents (mainly aspirin), 1.38% for lipid-lowering agents, and 3.11% for RAS-acting agents; the corresponding figures for secondary prevention (i.e., use of CV drugs among people with CVD) were 13.97%, 9.35%, and 7.39%. In conclusion, despite highly prevalent cardiovascular risk factors and CVDs, a fairly low proportion of the rural-dwelling older adults take CV medications for primary and secondary prevention. Notably, TCM products are among the most commonly used CV drugs. These results call for additional efforts to promote implementation of the evidence-based recommendations for prevention of CVDs in the primary care settings.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Annan medicin och hälsovetenskapx Gerontologi, medicinsk/hälsovetenskaplig inriktning0 (SwePub)305022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Other Medical and Health Sciencesx Gerontology, specialising in Medical and Health Sciences0 (SwePub)305022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Geriatrik0 (SwePub)302222 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Geriatrics0 (SwePub)302222 hsv//eng
653 a cardiovascular drugs
653 a cardiovascular disease
653 a prevalence
653 a prevention
653 a rural
7001 a Ren, Yifei4 aut
7001 a Hou, Tingting4 aut
7001 a Han, Xiaolei4 aut
7001 a Dong, Yi4 aut
7001 a Wang, Yongxiang4 aut
7001 a Zhang, Qinghua4 aut
7001 a Liu, Rui4 aut
7001 a Xu, Shan4 aut
7001 a Wang, Lidan4 aut
7001 a Du, Yifeng4 aut
7001 a Qiu, Chengxuanu Karolinska Institutet,Stockholms universitet,Centrum för forskning om äldre och åldrande (ARC), (tills m KI),Shandong First Medical University, China4 aut
7102 a Stockholms universitetb Centrum för forskning om äldre och åldrande (ARC), (tills m KI)4 org
7730 t Frontiers in Pharmacologyd : Frontiers Media SAg 11q 11x 1663-9812
8564 u https://doi.org/10.3389/fphar.2020.608136y Fulltext
8564 u https://www.frontiersin.org/articles/10.3389/fphar.2020.608136/pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-190647
8564 8u https://doi.org/10.3389/fphar.2020.608136
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:145543924

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy